Reported Q: Q1 2025 Rev YoY: +15.9% EPS YoY: +455.6% Move: +1.40%
Healthpeak Properties Inc
DOC
$17.08 1.40%
Exchange NYSE Sector Real Estate Industry REIT Healthcare Facilities
Q1 2025
Published: Apr 25, 2025

Company Status Snapshot

Fast view of the latest quarter outcome for DOC

Reported

Report Date

Apr 25, 2025

Quarter Q1 2025

Revenue

702.89M

YoY: +15.9%

EPS

0.06

YoY: +455.6%

Market Move

+1.40%

Previous quarter: Q4 2024

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

  • Revenue of $702.89M up 15.9% year-over-year
  • EPS of $0.06 increased by 455.6% from previous year
  • Gross margin of 22.9%
  • Net income of 42.83M
  • "We completed an additional 4.5 million square feet since January 1 with additional markets in the pipeline." - Scott Brinker
DOC
Company DOC

Executive Summary

Healthpeak Properties reported Q1 2025 results that reinforced the company’s multi-segment diversification and balance-sheet resilience, even as the Life Science (Lab) segment faced ongoing policy- and capital-raising headwinds. Revenue rose 15.9% YoY to $702.9 million, supported by robust performance in Outpatient Medical and CCRCs, while Operating Income declined on a quarterly basis due to mix and revaluations, with Net Income up sharply YoY and QoQ driven by favorable non-cash and financing dynamics. FFO adjusted per share came in at $0.46 and AFFO per share at $0.43, underpinning Healthpeak’s ability to fund development and buybacks within a disciplined capital framework.

Management emphasized a diversified portfolio (Outpatient Medical >50% of the platform post-merger with Physicians Realty Trust), ongoing NOI growth in key segments, and a commitment to maintaining leverage in the mid-5x range while preserving liquidity (~$2.8 billion) and enhancing capital flexibility via asset sales and stock repurchases. The call highlighted ongoing leasing momentum: 450,000 sq ft signed year-to-date in Life Sciences, a robust LOI pipeline (≈400,000 sq ft), and continued progress in internalization of property management and portfolio enhancements. Management also signaled cautious optimism on the Life Science cash-flow dynamics, noting potential near-term pressure from capital markets and regulatory shifts, yet outlining potential inflection points from U.S. policy and FDA-era modernization that could support demand for life-science and related real estate.

Looking forward, Healthpeak reaffirmed its guidance: FFO per share of $1.81–$1.87 and blended same-store NOI growth of 3–4%, with leverage target mid-5s. The company’s strategic actions—West Cambridge master plan development with Hines, a measured development and loan investment program, and selective asset dispositions—should support long-term value creation, though near-term earnings trajectory remains sensitive to life-science funding cycles and broader policy developments.

Key Performance Indicators

Revenue
Increasing
702.89M
QoQ: 0.70% | YoY: 15.88%
Gross Profit
Increasing
161.20M
22.93% margin
QoQ: -61.71% | YoY: 12.25%
Operating Income
Decreasing
60.42M
QoQ: -50.71% | YoY: -44.50%
Net Income
Increasing
42.83M
QoQ: 841.90% | YoY: 541.52%
EPS
Increasing
0.06
QoQ: 837.50% | YoY: 455.56%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q1 2025 702.89 0.06 +15.9% View
Q4 2024 697.99 0.01 +415.2% View
Q3 2024 700.40 0.12 +405.5% View
Q2 2024 695.50 0.21 +414.8% View
Q1 2024 606.56 0.01 +351.5% View